Importer of Controlled Substances; Notice of Registration

By Notice dated January 17, 1995, and published in the **Federal Register** on January 25, 1995, (60 FR 4925), Knight Seed Company, Inc., 151 W. 126th Street, Burnsville, Minnesota 55337, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Marihuana (7360), a basic class of controlled substance listed in Schedule I.

No comments or objections have been received. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1311.42, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: March 8, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–6219 Filed 3–13–95; 8:45 am]

BILLING CODE 4410–09–M

[Docket No. 94–52]

Mallinckrodt Chemical, Inc.; St. Louis, Missouri; Notice of Administrative Hearing, Summary of Comments and Objections; Notice of Hearing

This Notice of Administrative Hearing, Summary of Comments and Objections, regarding the application of Mallinckrodt Chemical, Inc. (Mallinckrodt) for registration as a bulk manufacturer of methylphenidate, a Schedule II controlled substance, is published pursuant to 21 CFR 1301.43(a). Notice was published in the **Federal Register** on March 28, 1994,[1] and May 13, 1994,[2] respectively, naming the applicant and stating that the applicant has applied to be registered as a bulk manufacturer of methylphenidate.

On June 14, 1994, MD Pharmaceutical Inc. (MD Pharmaceutical) filed an objection and requested a hearing on the application, in accordance with 21 CFR 1301.43(a). Notice is hereby given that a hearing with respect to the Mallinckrodt's application to be registered as a bulk manufacturer of methylphenidate will be conducted pursuant to the provisions of 5 U.S.C. 552 et seq. and 21 CFR 1301.43 et seq. and 1316.41 et seq.

[1] 59 FR 14426.

[2] 59 FR 25126.

Hearing Date: The hearing is scheduled for May 2 through 5 1994, commencing at 9:30 a.m. on May 2, 1995, at the Drug Enforcement Administration Headquarters, 600 Army Navy Drive, Hearing Room, Room E–2103, Arlington, Virginia.

Notice of Appearance: Any person entitled to participate in this hearing pursuant to 21 CFR 1301.43(a), and interested in doing so, may participate by filing a notice of intention to participate in accordance with 21 CFR 1301.54, in duplicate, with the Hearing Clerk, Office of the Administrative Law Judge, Drug Enforcement Administration, Washington, D.C. 20537, within 30 days of the date of publication of this notice in the **Federal Register**. Each notice of appearance must be in the form prescribed in 21 CFR 1316.48. The entities whose comment and/or objections are referenced below need not file a notice of intention to participate.

For Further Information Contact: Ms. Helen Farmer, Hearing Clerk, Drug Enforcement Administration, Washington, D.C. 20537; Telephone (202) 307–8188.

Summary of Comments and Objections

Drug Enforcement Adminstration Comments

The Government does not know of any reason to deny Mallinckrodt's application.

MD Pharmaceutical's Comments and Objections

MD Pharmaceutical intends to show that the registration of Mallinckrodt to manufacture methylphenidate in its generic form is not consistent with the public interest as that term is used in 21 U.S.C. 823(a). MD Pharmaceutical seeks to establish that Mallinckrodt does not satisfy the public interest standard by showing that: (1) Mallinckrodt does not meet the Controlled Substances Act requirements for registration as a bulk manufacturer of methylphenidate; and (2) the Food and Drug Administration has cited Mallinckrodt frequently in the twelve months preceding MD Pharmaceutical's hearing request for serious violations directly related to the manufacture and distribution of adulterated drug products.

Mallinckrodt's Comments

Mallinckrodt intends to establish that it meets the requirements of 21 USC 823(a) and, therefore, qualifies for registration as a manufacturer of methylphenidate. Mallinckrodt seeks to demonstrate that it satisfies the requirements of § 823(a) by showing that: (1) Mallinckrodt is registered as a bulk manufacturer of numerous Schedule II controlled substances; (2) Mallinckrodt has been a bulk manufacturer of narcotics for more than ninety-five years; (3) Mallinckrodt has a long history of successful controls against diversion and is prepared to apply that experience to its Mallinckrodt production; (4) Mallinckrodt has proven its commitment to insuring that there is an adequate and uninterrupted supply of bulk narcotics; (5) Mallinckrodt has a proven track record of promoting technical advances in the field of bulk narcotics manufacture; and (6) Mallinckrodt has used its special status as a registered manufacturer of narcotics to promote public health and safety.

Dated: March 8, 1995.

Stephen H. Greene,

Deputy Administrator, Drug Enforcement Administration.

[FR Doc. 95–6159 Filed 3–13–95; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated January 17, 1995, and published in the **Federal Register** on January 25, 1995, (60 FR 4926), MD Pharmaceutical, Inc., 3501 West Garry Avenue, Santa Ana, California 92704, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methylphenidate (1724)	II
Diphenoxylate (9170)	II

No comments or objections have been received. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, Section 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: March 8, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–6220 Filed 3–13–95; 8:45 am]

BILLING CODE 4410–09–M